Cramer Quick Take: Investing in Allergan

NEW YORK (TheStreet) --When it comes to Allergan (AGN) , it's all about the company's pipeline of new products, Jim Cramer told Nicole Urken at TheStreet.com Wednesday. That's why he's now more bullish than ever on the company.

Cramer explained that Allergan normally issues guidance below Street estimates, then handily beat them. But this quarter the company offered up guidance above estimates, a strong signal that it remains very confident about its prospects for 2013.

Cramer said that typically Allergan delivers one big drug a year, then has to train doctors on how to administer it. But this year the company has not one but two drugs, neither of which involve significant training efforts.

To sign up for Jim Cramer's free Booyah! newsletter, with all of his latest articles and videos, please click here.